<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02684630</url>
  </required_header>
  <id_info>
    <org_study_id>CTS-5054</org_study_id>
    <nct_id>NCT02684630</nct_id>
  </id_info>
  <brief_title>Trima Accel® System Post Count Algorithm Study</brief_title>
  <official_title>A Multicenter Study to Evaluate Modified Postcount Algorithm Software on the Trima Accel® System in Volunteer Blood Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Terumo BCT</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Terumo BCT</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to optimize collected platelet yields in single and double
      platelet collections, while maintaining donor postplatelet count of &gt;100,000/µL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open-label, non-randomized study to evaluate Trima Accel System
      modified postcount algorithm software.

      Platelets will be collected according to the Trima Accel System Operator's Manual. Collection
      procedures will include those in which:

        1. a single platelet product is collected

        2. a double platelet product is collected, with or without other components.

      Study participation will be up to 8 days. The apheresis procedure can last from 25 to 150
      minutes, dependent upon the product(s) to be collected, machine configuration, donor
      parameters, the quality of the vascular access, and the tolerance of the donor to the citrate
      anticoagulant.

      Donors will have one apheresis procedure and follow-up with any serious adverse events for 7
      days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 28, 2016</start_date>
  <completion_date type="Actual">May 28, 2016</completion_date>
  <primary_completion_date type="Actual">May 28, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Donor Postprocedure Platelet Count Following Donation of Single Platelet Product</measure>
    <time_frame>The blood draw to determine postprocedure platelet count will occur ≥ 15 minutes after the end of apheresis</time_frame>
    <description>The primary endpoint for this study was the postprocedure participant platelet count for participants who have completed a single or double platelet collection. A procedure was a success if the participant's postprocedure platelet count was ≥ 100,000 platelets/μL. A procedure was a failure if the participant's postprocedure platelet count was &lt; 100,000 platelets/μL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Donor Postprocedure Platelet Count Following Donation of Double Platelet Product</measure>
    <time_frame>The blood draw to determine post procedure platelet count will occur ≥ 15 minutes after the end of apheresis</time_frame>
    <description>The primary endpoint for this study was the participant's postprocedure platelet count after completing a double platelet collection. A procedure was considered a success if the participant's postprocedure platelet count was ≥ 100,000 platelets/μL.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Single Platelet Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adult volunteer blood donors that qualify for a single unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double Platelet Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adult volunteer blood donors that qualify for a double unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Trima Accel System</intervention_name>
    <description>Platelet Apheresis Procedure</description>
    <arm_group_label>Single Platelet Product</arm_group_label>
    <arm_group_label>Double Platelet Product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years.

          -  Meets Blood Center criteria for blood donation and is scheduled for an apheresis
             procedure that includes a single or double platelet product. These criteria are based
             on FDA Regulations and American Association of Blood Banks (AABB) Guidelines.

          -  Appears to have adequate venous access to obtain a postprocedure platelet count.

          -  Has given written informed consent.

        Exclusion Criteria:

          -  Has undergone a splenectomy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather Pidcoke, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Terumo BCT, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Diego Blood Bank</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bonfils Blood Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>February 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2016</study_first_posted>
  <results_first_submitted>April 19, 2017</results_first_submitted>
  <results_first_submitted_qc>May 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 8, 2017</results_first_posted>
  <last_update_submitted>June 16, 2017</last_update_submitted>
  <last_update_submitted_qc>June 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>131 volunteers signed consent and were enrolled, but 3 were screen fails and therefore did not participate in the study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Single Platelet Product</title>
          <description>Healthy adult volunteer blood donors that qualify for a single unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel System.
Trima Accel System: Platelet Apheresis Procedure</description>
        </group>
        <group group_id="P2">
          <title>Double Platelet Product</title>
          <description>Healthy adult volunteer blood donors that qualify for a double unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel System.
Trima Accel System: Platelet Apheresis Procedure</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Safety Population was used to evaluate participant demographics and treatment emergent adverse events (TEAE).</population>
      <group_list>
        <group group_id="B1">
          <title>Single Platelet Product</title>
          <description>Healthy adult volunteer blood donors that qualify for a single unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel System.
Trima Accel System: Platelet Apheresis Procedure</description>
        </group>
        <group group_id="B2">
          <title>Double Platelet Product</title>
          <description>Healthy adult volunteer blood donors that qualify for a double unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel System.
Trima Accel System: Platelet Apheresis Procedure</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="128"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age ≥ 18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (in)</title>
          <units>inches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.9" spread="3.95"/>
                    <measurement group_id="B2" value="69.0" spread="3.43"/>
                    <measurement group_id="B3" value="69.0" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (lbs)</title>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="190.3" spread="37.59"/>
                    <measurement group_id="B2" value="191.6" spread="31.23"/>
                    <measurement group_id="B3" value="191.0" spread="34.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Blood Volume (mL)</title>
          <units>mililiters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5214.3" spread="905.93"/>
                    <measurement group_id="B2" value="5285.7" spread="735.86"/>
                    <measurement group_id="B3" value="5249.5" spread="824.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Donor Postprocedure Platelet Count Following Donation of Single Platelet Product</title>
        <description>The primary endpoint for this study was the postprocedure participant platelet count for participants who have completed a single or double platelet collection. A procedure was a success if the participant’s postprocedure platelet count was ≥ 100,000 platelets/μL. A procedure was a failure if the participant’s postprocedure platelet count was &lt; 100,000 platelets/μL.</description>
        <time_frame>The blood draw to determine postprocedure platelet count will occur ≥ 15 minutes after the end of apheresis</time_frame>
        <population>The Full Analysis Set (FAS) included all participants that completed the study and did not meet any of the protocol exclusion criteria. A participant could only have 1 product included in the FAS. The FAS was used to examine the primary and secondary endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Platelet Product</title>
            <description>Healthy adult volunteer blood donors that qualify for a single unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).
Trima Accel System: Platelet Apheresis Procedure</description>
          </group>
          <group group_id="O2">
            <title>Double Platelet Product</title>
            <description>Healthy adult volunteer blood donors that qualify for a double unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).
Trima Accel System: Platelet Apheresis Procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Donor Postprocedure Platelet Count Following Donation of Single Platelet Product</title>
          <description>The primary endpoint for this study was the postprocedure participant platelet count for participants who have completed a single or double platelet collection. A procedure was a success if the participant’s postprocedure platelet count was ≥ 100,000 platelets/μL. A procedure was a failure if the participant’s postprocedure platelet count was &lt; 100,000 platelets/μL.</description>
          <population>The Full Analysis Set (FAS) included all participants that completed the study and did not meet any of the protocol exclusion criteria. A participant could only have 1 product included in the FAS. The FAS was used to examine the primary and secondary endpoints.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Success (n)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failure (n)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Sample Size Determination:
Up to 160 participants were to be enrolled in this study to ensure 60 evaluable single platelet product collections and 60 evaluable double platelet product collections. This number was chosen to meet the FDA requirements of 95% of postprocedure participant platelet count of ≥ 100,000 platelets/μL with 95% confidence.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A procedure is a success if the donor's post-procedure platelet count is ≥ 100,000 platelets/μL, lower one-sided 95% confidence interval for the procedure success rate is at least 95%.</non_inferiority_desc>
            <param_type>Simple sample proportion</param_type>
            <param_value>1.00</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>0.951</ci_lower_limit>
            <estimate_desc>Estimated proportion is 100%. Hence standard deviation is estimated as 0.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Donor Postprocedure Platelet Count Following Donation of Double Platelet Product</title>
        <description>The primary endpoint for this study was the participant’s postprocedure platelet count after completing a double platelet collection. A procedure was considered a success if the participant’s postprocedure platelet count was ≥ 100,000 platelets/μL.</description>
        <time_frame>The blood draw to determine post procedure platelet count will occur ≥ 15 minutes after the end of apheresis</time_frame>
        <population>The Full Analysis Set (FAS) included all participants that completed the study and did not meet any of the protocol exclusion criteria. A participant could only have 1 product included in the FAS. The FAS was used to examine the primary and secondary endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Platelet Product</title>
            <description>Healthy adult volunteer blood donors that qualify for a single unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel System.
Trima Accel System: Platelet Apheresis Procedure</description>
          </group>
          <group group_id="O2">
            <title>Double Platelet Product</title>
            <description>Healthy adult volunteer blood donors that qualify for a double unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel System.
Trima Accel System: Platelet Apheresis Procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Donor Postprocedure Platelet Count Following Donation of Double Platelet Product</title>
          <description>The primary endpoint for this study was the participant’s postprocedure platelet count after completing a double platelet collection. A procedure was considered a success if the participant’s postprocedure platelet count was ≥ 100,000 platelets/μL.</description>
          <population>The Full Analysis Set (FAS) included all participants that completed the study and did not meet any of the protocol exclusion criteria. A participant could only have 1 product included in the FAS. The FAS was used to examine the primary and secondary endpoints.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Success (n)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failure (n)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample Size Determination:
Up to 160 participants were to be enrolled in this study to ensure 60 evaluable single platelet product collections and 60 evaluable double platelet product collections. This number was chosen to meet the FDA requirements of 95% of postprocedure participant platelet count of ≥ 100,000 platelets/μL with 95% confidence.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A procedure is a success if the donor’s post-procedure platelet count is ≥ 100,000 platelets/μL, lower one-sided 95% confidence interval for the procedure success rate is at least 95%.</non_inferiority_desc>
            <param_type>Simple sample proportion</param_type>
            <param_value>1.00</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>0.951</ci_lower_limit>
            <estimate_desc>Estimated proportion is 100%. Hence standard deviation is estimated as 0.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events that occurred during and up to 24 hours after the apheresis procedure were recorded.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Single Platelet Product</title>
          <description>Healthy adult volunteer blood donors that qualify for a single unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).
Trima Accel System: Platelet Apheresis Procedure</description>
        </group>
        <group group_id="E2">
          <title>Double Platelet Product</title>
          <description>Healthy adult volunteer blood donors that qualify for a double unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).
Trima Accel System: Platelet Apheresis Procedure</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA Version 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Extravasation</sub_title>
                <description>General disorders and administration site conditions including injection site extravasation.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Citrate Toxicity</sub_title>
                <description>Metabolism and nutrition disorders including overall and citrate toxicity.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <description>Nervous system disorders including paraesthesia.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <description>Nervous system disorders including presyncope.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Heather Pidcoke, MD, PhD</name_or_title>
      <organization>Terumo BCT, Inc.</organization>
      <phone>(303) 231-4805</phone>
      <email>Heather.Pidcoke@terumobct.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

